Safety of Arthritis Drugs, Day 3, Part 1
At a joint meeting of the Arthritis and Drug Safety and Risk Management Advisory Committees, members discussed the safety of drugs called “C… read more
At a joint meeting of the Arthritis and Drug Safety and Risk Management Advisory Committees, members discussed the safety of drugs called “COX-2” inhibitors, such as Vioxx and Celebrex. Dr. Constantine Lyketsos talked about ending a clinical trial because of an apparent link between some uses of “COX-2” inhibitors and heart attacks. Professor Milton Packer showed slides and talked about analyzing cardiac events in research on small samples. Both responded to questions from committee members after their presentations. close
People in this video
-
Kimberly Topper Executive Secretary U.S. Food and Drug Administration->Center for Drug Evaluation and Research
Hosting Organization
More Videos From
Safety of Arthritis Drugs, Day 3,
More VideosRelated Video
-
Safety of Arthritis Drugs, Day 2, Part 1
Physicians spoke at a meeting to assess the safety records of arthritis drugs. Representatives for the drug Arcoxia and …
-
Safety of Arthritis Drugs, Day 1, Part 2
A joint meeting of the Food and Drug Administration’s Arthritis and Drug Safety and Risk Management Advisory Committees …
-
Safety of Arthritis Drugs, Day 1, Part 3
Dr. Villalba and others spoke at a meeting to assess the safety records of arthritis drugs. They talked about testing an…
-
Open Phones
Telephone lines were open for viewer comments on the question, “Should painkiller Celebrex be pulled from the market?”